GPCR on Nasdaq
Structure Therapeutics Inc.
In its 2026 annual report the company says: “We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors.”4 It is headquartered in South San Francisco, California.1 Its shares trade on Nasdaq under the symbol GPCR.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerGPCR on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSouth San Francisco, California1
- Incorporated inCayman Islands2
- Business address601 Gateway Blvd Suite 900, South San Francisco, Ca 940802
- Filer categoryLarge accelerated filer2
- Legal formOther
See how the biggest companies compare on our leaderboards
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $225.3M | $108.8M | $70.1M |
| General and administrative | $61.6M | $49.4M | $32.7M |
| Other license income | -$100.0M | ||
| Gains on sale of non-financial assets | -$10.2M | ||
| Total operating expenses | $176.6M | $158.2M | $102.8M |
| Loss from operations | -$176.6M | -$158.2M | -$102.8M |
| Interest and other income, net | $35.9M | $36.0M | $13.4M |
| Loss before provision for income taxes | -$140.7M | -$122.2M | -$89.4M |
| Provision for income taxes | $515.0K | $310.0K | $236.0K |
| Net loss attributable to ordinary shareholders | -$141.2M | -$122.5M | -$89.6M |
| Net loss per share, basic | -$0.80 | -$0.78 | -$0.81 |
| Net loss per share, diluted | -$0.80 | -$0.78 | -$0.81 |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic | 177.6M shares | 157.9M shares | 110.2M shares |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted | 177.6M shares | 157.9M shares | 110.2M shares |
| Unrealized gain on investments, net | $140.0K | $393.0K | $631.0K |
| Total other comprehensive income | $140.0K | $393.0K | $631.0K |
| Comprehensive loss | -$141.1M | -$122.1M | -$89.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $799.6M | $169.5M | ||
| Short-term investments | $646.6M | $714.0M | ||
| Other receivable | $100.0M | |||
| Prepaid expenses and other current assets | $24.1M | $7.7M | ||
| Total current assets | $1.6B | $891.2M | ||
| Property and equipment, net | $6.7M | $3.5M | ||
| Operating right-of-use assets | $6.2M | $3.5M | ||
| Other non-current assets | $717.0K | $5.1M | ||
| Total assets | $1.6B | $903.3M | ||
| Accounts payable | $13.9M | $8.0M | ||
| Accrued expenses and other current liabilities | $46.5M | $26.3M | ||
| Operating lease liabilities, current portion | $2.9M | $1.7M | ||
| Total current liabilities | $63.3M | $36.0M | ||
| Operating lease liabilities, net of current portion | $3.6M | $2.2M | ||
| Other non-current liabilities | $647.0K | $302.0K | ||
| Total liabilities | $67.5M | $38.5M | ||
| Ordinary shares - $0.0001 par value; 500,000 shares authorized as of December 31, 2025 and December 31, 2024; 212,513 and 171,860 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $21.0K | $17.0K | ||
| Additional paid-in capital | $2.0B | $1.2B | ||
| Accumulated other comprehensive income | $1.1M | $914.0K | ||
| Accumulated deficit | -$470.3M | -$329.1M | ||
| Total shareholders' equity | $1.5B | $864.8M | $453.0M | -$115.1M |
| Total liabilities and shareholders' equity | $1.6B | $903.3M | ||
| Undesignated shares, par value | $0.00 | $0.00 | ||
| Undesignated shares, shares authorized | 100.0M shares | 100.0M shares | ||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized | 500.0M shares | 500.0M shares | ||
| Ordinary shares, shares issued | 212.5M shares | 171.9M shares | ||
| Ordinary shares, shares outstanding | 212.5M shares | 171.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $799.6M | $169.5M | ||
| Short-term investments | $646.6M | $714.0M | ||
| Other receivable | $100.0M | |||
| Prepaid expenses and other current assets | $24.1M | $7.7M | ||
| Total current assets | $1.6B | $891.2M | ||
| Property and equipment, net | $6.7M | $3.5M | ||
| Operating right-of-use assets | $6.2M | $3.5M | ||
| Other non-current assets | $717.0K | $5.1M | ||
| Total assets | $1.6B | $903.3M | ||
| Accounts payable | $13.9M | $8.0M | ||
| Accrued expenses and other current liabilities | $46.5M | $26.3M | ||
| Operating lease liabilities, current portion | $2.9M | $1.7M | ||
| Total current liabilities | $63.3M | $36.0M | ||
| Operating lease liabilities, net of current portion | $3.6M | $2.2M | ||
| Other non-current liabilities | $647.0K | $302.0K | ||
| Total liabilities | $67.5M | $38.5M | ||
| Ordinary shares - $0.0001 par value; 500,000 shares authorized as of December 31, 2025 and December 31, 2024; 212,513 and 171,860 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $21.0K | $17.0K | ||
| Additional paid-in capital | $2.0B | $1.2B | ||
| Accumulated other comprehensive income | $1.1M | $914.0K | ||
| Accumulated deficit | -$470.3M | -$329.1M | ||
| Total shareholders' equity | $1.5B | $864.8M | $453.0M | -$115.1M |
| Total liabilities and shareholders' equity | $1.6B | $903.3M | ||
| Undesignated shares, par value | $0.00 | $0.00 | ||
| Undesignated shares, shares authorized | 100.0M shares | 100.0M shares | ||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized | 500.0M shares | 500.0M shares | ||
| Ordinary shares, shares issued | 212.5M shares | 171.9M shares | ||
| Ordinary shares, shares outstanding | 212.5M shares | 171.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$141.2M | -$122.5M | -$89.6M |
| Share-based compensation expense | $29.0M | $18.8M | $8.2M |
| Depreciation expense | $1.3M | $992.0K | $295.0K |
| Accretion of asset retirement obligation | $345.0K | $4.0K | $21.0K |
| Non-cash lease expense | $2.2M | $1.6M | $634.0K |
| Accretion of net investment discounts | -$15.6M | -$18.5M | -$6.0M |
| Gains on sale of non-financial assets | -$10.2M | ||
| Other receivable | -$100.0M | ||
| Prepaid expenses and other current assets | -$16.4M | -$1.4M | -$4.0M |
| Other non-current assets | $4.4M | -$5.1M | $15.0K |
| Accounts payable | $4.8M | $3.3M | -$860.0K |
| Accrued expenses and other current liabilities | $21.5M | $7.7M | $12.2M |
| Operating lease liabilities | -$2.3M | -$1.6M | -$315.0K |
| Net cash used in operating activities | -$222.2M | -$116.6M | -$79.5M |
| Purchases of short-term investments | -$547.4M | -$702.5M | -$417.4M |
| Proceeds from maturities of short-term investments | $630.5M | $344.9M | $151.2M |
| Purchases of property and equipment | -$3.6M | -$1.3M | -$2.2M |
| Proceeds from sale of non-financial asset | $10.2M | ||
| Net cash provided by (used in) investing activities | $89.8M | -$358.9M | -$268.3M |
| Proceeds from issuance of pre-funded warrants in 2025 Follow-On Offering, net of underwriting discounts and commissions | $94.0M | ||
| Proceeds from issuance of ordinary shares in initial public offering, net of underwriting discounts and commissions | $172.3M | ||
| Proceeds from private placement financing, gross | $300.0M | ||
| Payments of offering costs | -$2.0M | -$1.8M | -$21.6M |
| Proceeds from issuance of ordinary shares under employee share purchase plan | $921.0K | $632.0K | |
| Proceeds from exercise of share options | $4.5M | $1.9M | $800.0K |
| Payment of taxes on restricted share units withheld for taxes | -$618.0K | ||
| Net cash provided by financing activities | $762.5M | $515.3M | $451.5M |
| Net change in cash and cash equivalents | $630.1M | $39.7M | $103.7M |
| Offering costs included in accounts payable and accrued expenses and other current liabilities | $442.0K | $100.0K | $53.0K |
| Operating lease right-of-use assets obtained in exchange for new lease liabilities | $4.9M | $5.5M | |
| Depository issuance cost offset | $1.5M | ||
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | $894.0K | $48.0K | |
| Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering | $200.0M | ||
| Recognition of asset retirement obligation | $277.0K | ||
| Conversion of non-voting ordinary shares into ordinary shares | $1.0K | ||
| Exchange of ordinary shares to non-voting ordinary shares | $1.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Structure Therapeutics Inc. sits at the top of its group. 10 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Structure Therapeutics Inc.
- FMR LLC Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest Aug 6, 2026 (7 filings since Feb 10, 2023)
- BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest Feb 17, 2026 (4 filings since Feb 13, 2023)
- Deep Track Capital, LP Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest Feb 13, 2026 (7 filings since Feb 3, 2023)
- Wellington Management Company Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest Feb 10, 2026 (7 filings since Feb 6, 2024)
- Avoro Capital Advisors LLC Filed SCHEDULE 13G on Structure Therapeutics Inc., latest Nov 14, 2025 (3 filings since Feb 14, 2024)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest Nov 14, 2025 (5 filings since Nov 14, 2024)
- Capital Research Global Investors Filed SCHEDULE 13G/A on Structure Therapeutics Inc., latest May 13, 2025 (2 filings since Nov 12, 2024)
- RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Structure Therapeutics Inc., latest Nov 14, 2024 (2 filings since May 30, 2024)
- FIL Ltd Filed SC 13G/A on Structure Therapeutics Inc., latest Feb 9, 2024 (2 filings since Feb 10, 2023)
- Structure Therapeutics Inc. South San Francisco, California
- Aconcagua Bio, Inc. Subsidiary · Delaware, United States
- Annapurna Bio, Inc. Subsidiary · Delaware, United States
- Basecamp Bio Inc. Subsidiary · Cayman Islands
- Gangkhar Bio Inc. Subsidiary · Delaware, United States
- Gasherbrum Bio, Inc. Subsidiary · Delaware, United States
- Gimigela Bio, Inc. Subsidiary · Delaware, United States
- Lhotse Bio, Inc. Subsidiary · Delaware, United States
- ShouTi Hong Kong Limited Subsidiary · Hong Kong
- Structure Therapeutics USA Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Structure Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $9.6M6 Dec 31, 2025 | $5.1M6 Dec 31, 2024 | +88.2% |
| Accumulated depreciation | $3.0M6 Dec 31, 2025 | $1.6M6 Dec 31, 2024 | +81.5% |
| Property and equipment, net | $6.7M6 Dec 31, 2025 | $3.5M6 Dec 31, 2024 | +91.3% |
| Operating-lease assets (leased space) | $6.2M6 Dec 31, 2025 | $3.5M6 Dec 31, 2024 | +76.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $799.6M6 Dec 31, 2025 | $169.5M6 Dec 31, 2024 | +371.7% |
| Marketable securities, current | $646.6M6 Dec 31, 2025 | $714.0M6 Dec 31, 2024 | −9.4% |
Properties, in its own words
Our principal executive office is located in South San Francisco, California where we lease a total of approximately 11,800 square feet of office space that we use for our administrative and other activities. The lease commenced in July 2023 and will expire on August 31, 2027. In addition, we lease a total of 22,365 square feet of office space located in South San Francisco, California to expand our corporate headquarters. The lease commenced in March 2025 and will expire on October 31, 2029. We also have a development and operations office located in Shanghai, China where we lease a total of approximately 22,500 square feet of office space. This lease expires on December 31, 2026. We also lease a total of approximately 8,400 square feet of laboratory space located in Shanghai, China for our research and development activities. This lease expires on January 31, 2027. In addition, we lease approximately 5,000 square feet of office and laboratory space located in Shanghai, China for our research and development activities. This lease commenced in June 2025 and will expire on August 9, 2028. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.
Item 2 of the 10-K filed Feb 26, 2026.4
Leadership
Who has led Structure Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerRaymond C. Stevens Feb 2, 2023 to now10
- Chief financial officerJun Yoon Feb 2, 2023 to now11
- Chief operating officerMatthew Lang Apr 23, 2026 to now12
Board members and other officers (14)
- Chief Commercial OfficerJohn Joseph Berrios Aug 7, 2026 to now13
- Chief Development OfficerAshley Hall Sep 20, 2024 to now14
- Chief Medical OfficerCrespo Blas Coll Sep 20, 2024 to now15
- Chief Medical OfficerMark Allen Bach Feb 2, 2023 to Mar 20, 202416
- Chief Business OfficerMelita Sun Jung Feb 2, 2023 to Feb 9, 202317
- Chief Scientific OfficerXichen Lin Feb 2, 2023 to now18
- Chief Technology OfficerYingli Ma Feb 2, 2023 to now19
- Board memberDaniel G. Welch Feb 2, 2023 to now20
- Board memberEric Dobmeier Feb 2, 2023 to now21
- Board memberJoanne Waldstreicher Feb 2, 2023 to now22
- Board memberRamy Farid Feb 2, 2023 to Feb 9, 202323
- Board memberRaymond C. Stevens Feb 2, 2023 to now10
- Board memberSharon Tetlow Feb 2, 2023 to now24
- Board memberTed W. Love Aug 4, 2023 to now25
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorChen Ming Yu named Oct 21, 2021 to Jan 10, 202226
- DirectorCuiping Gu named Oct 21, 2021 to Jan 10, 202226
- DirectorDaniel Auerbach named Oct 21, 2021 to Jan 10, 202226
- DirectorJessica Lifton named Oct 21, 2021 to Jan 10, 202226
- DirectorRobert Weisskoff named Oct 21, 2021 to Jan 10, 202226
- DirectorTing Xie named Oct 21, 2021 to Jan 10, 202226
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Aconcagua Bio, Inc. Delaware3
- Annapurna Bio, Inc. Delaware3
- Basecamp Bio Inc. Cayman Islands3
- Gangkhar Bio Inc. Delaware3
- Gasherbrum Bio, Inc. Delaware3
- Gimigela Bio, Inc. Delaware3
- Lhotse Bio, Inc. Delaware3
- ShouTi Hong Kong Limited Hong Kong3
- Structure Therapeutics USA Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- ShouTi Inc.Oct 21, 2021 to May 13, 20222
Timeline
- Sep 8, 20268-K Regulation FD disclosure; Other events27
- Aug 6, 20268-K Results of operations28
- Jun 18, 20268-K Shareholder vote29
- May 7, 20268-K Entered a material agreement; Results of operations; Other events30
- Apr 15, 20268-K Executive or director change; Regulation FD disclosure31
- Mar 16, 20268-K Regulation FD disclosure; Other events32
- Feb 26, 20268-K Results of operations33
- Jan 5, 20268-K Entered a material agreement34
- Dec 10, 20258-K Other events35
- Dec 8, 20258-K Regulation FD disclosure; Other events36
- Nov 6, 20258-K Results of operations37
- Aug 6, 20258-K Results of operations38
- Feb 2, 2023New chief executive Raymond C. Stevens becomes CEO10
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.37) a share, on Nov 6, 2025.39
When it reported results
- Aug 6, 2026Reported quarterly or annual results28
- May 7, 2026Reported quarterly or annual results30
- Feb 26, 2026Reported quarterly or annual results33
- Nov 6, 2025Reported quarterly or annual results37
- Aug 6, 2025Reported quarterly or annual results38
- May 8, 2025Reported quarterly or annual results40
- Feb 27, 2025Reported quarterly or annual results41
- Nov 13, 2024Reported quarterly or annual results42
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
270 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 36 major events, 115 insider forms, 39 large holders, 4 private raises, 59 other. The latest 20:
- Sep 22, 20264 EDGAR
- Sep 21, 2026144 EDGAR
- Sep 8, 20268-K EDGAR
- Sep 2, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20263 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 20264 EDGAR
- Jul 24, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 25, 2026144 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
The 270 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G/A, 7 filings Feb 10, 2023 to Aug 6, 202643
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 4 filings Feb 13, 2023 to Feb 17, 202644
- Deep Track Capital, LPSCHEDULE 13G/A, 7 filings Feb 3, 2023 to Feb 13, 202645
- Wellington Management CompanySCHEDULE 13G/A, 7 filings Feb 6, 2024 to Feb 10, 202646
- Avoro Capital Advisors LLCSCHEDULE 13G, 3 filings Feb 14, 2024 to Nov 14, 202547
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 5 filings Nov 14, 2024 to Nov 14, 202548
- Capital Research Global InvestorsSCHEDULE 13G/A, 2 filings Nov 12, 2024 to May 13, 202549
- RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 2 filings May 30, 2024 to Nov 14, 202450
- FIL LtdSC 13G/A, 2 filings Feb 10, 2023 to Feb 9, 202451
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Raymond Stevens, Ph.D.Chief Executive Officer and Director | 62 | $672.1K | $8.4M52 |
| 2025 | Jun YoonChief Financial Officer | 48 | $530.5K | $4.5M52 |
| 2025 | Blai Coll, M.D., Ph.D.Chief Medical Officer | 52 | $492.8K | $3.2M52 |
| 2025 | Xichen Lin, Ph.D.Chief Scientific Officer | 52 | $505.3K | $2.5M52 |
| 2025 | Yingli Ma, Ph.D.Chief Technology Officer | 52 | $429.8K | $2.0M52 |
| 2024 | Raymond Stevens, Ph.D.Chief Executive Officer and Director | 62 | $634.2K | $5.7M52 |
| 2024 | Xichen Lin, Ph.D.Chief Scientific Officer | 52 | $476.5K | $3.7M52 |
| 2024 | Blai Coll, M.D., Ph.D.Chief Medical Officer | 52 | $449.1K | $3.5M52 |
| 2024 | Jun YoonChief Financial Officer | 48 | $482.3K | $2.8M52 |
| 2023 | Raymond Stevens, Ph.D.Chief Executive Officer and Director | 62 | $595.9K | $7.4M52 |
| 2023 | Jun YoonChief Financial Officer | 48 | $441.3K | $3.7M52 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $165.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2021 | $107.0M | $107.0M |
| 2020 | $26.0M | $26.0M |
| 2019 | $32.0M | $32.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Dec 15, 2021Raised $7 million in a private offering of equity26 Form D: 8 investors so far Form D
- Jul 30, 2021Raised $100 million in a private offering of equity53 Form D: 30 investors so far Form D
- Mar 11, 2020Raised $26 million in a private offering of equity54 Form D: 9 investors so far Form D
- Apr 29, 2019Raised $32 million in a private offering of equity55 Form D: 6 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 7,810,306 | $419.2M | 0.0% | −593,143 |
| Wellington Management Group Llp | 7,379,433 | $396.1M | 0.1% | +119,146 |
| Avoro Capital Advisors LLC | 6,555,555 | $351.8M | 3.2% | No change |
| Jupiter Topco LLC | 5,204,212 | $279.3M | 0.1% | New |
| Deep Track Capital, LP | 4,740,072 | $254.4M | 3.7% | +460,224 |
| Bvf Inc/il | 3,366,823 | $180.7M | 4.6% | −92,535 |
| Morgan Stanley | 2,806,640 | $150.6M | 0.0% | +501,183 |
| Orbimed Advisors LLC | 2,209,400 | $118.6M | 2.3% | +733,997 |
| Principal Financial Group Inc | 1,752,753 | $94.1M | 0.0% | −1,011 |
| American Century Companies Inc | 1,682,179 | $90.3M | 0.0% | +244,148 |
| Rtw Investments, LP | 1,607,507 | $86.3M | 0.7% | New |
| Driehaus Capital Management LLC | 1,553,219 | $83.4M | 0.5% | −24,137 |
| Baker Bros. Advisors LP | 1,432,529 | $76.9M | 0.4% | No change |
| Casdin Capital, LLC | 1,175,000 | $63.1M | 3.2% | No change |
| Deerfield Management Company, L.P. | 1,086,000 | $58.3M | 0.7% | +318,007 |
| Capitolis Liquid Global Markets LLC | 1,041,100 | $55.9M | 0.2% | −110,200 |
| Siren, L.L.C. | 872,967 | $46.9M | 1.0% | −455,731 |
| Pacific Heights Asset Management LLC | 800,000 | $42.9M | 1.4% | +50,000 |
| Rock Springs Capital Management LP | 640,317 | $34.4M | 1.7% | +100 |
| Aberdeen Group plc | 639,915 | $34.3M | 0.0% | +248,106 |
| Franklin Resources Inc | 578,839 | $31.1M | 0.0% | +47,244 |
| Bank Of America Corp /de/ | 563,422 | $30.2M | 0.0% | +336,290 |
| Alliancebernstein L.P. | 611,708 | $29.5M | 0.0% | −27,105 |
| BlackRock, Inc. | 511,149 | $27.4M | 0.0% | +69,174 |
| Logos Global Management LP | 500,000 | $26.8M | 1.2% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Oct 4, 2023 | Thomas R Carper, Senate | Sale | $1,001 - $15,000 | +141.1% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Structure Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARStructure Therapeutics Inc.1
- CIK0001888886
- Employer ID (EIN)98-14808214
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inCayman Islands4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address601 Gateway Blvd Suite 900, South San Francisco, CA 940801
- Phone(650) 457-19781
- Shares outstanding213,929,572 as of Jul 31, 20268
- Public float$834.9M as of Jun 30, 20254
- AuditorErnst & Young LLP, San Mateo, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceOct 21, 20211
- Filings270 in all: 4 (88), 8-K (36), 3 (22), SCHEDULE 13G/A (17), 10-Q (11), SC 13G/A (10), CORRESP (9), SC 13G (9)1
All 33 form types
UPLOAD (8), 4/A (5), 10-K (4), 144 (4), D (4), EFFECT (4), S-8 (4), 424B5 (3), ARS (3), DEF 14A (3), S-1 (3), SCHEDULE 13G (3), 10-Q/A (2), 424B4 (2), DRS (2), DRS/A (2), DRSLTR (2), S-1MEF (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), F-6 (1), NT 10-Q (1), S-1/A (1), S-3ASR (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 23, 2026
Latest 8-K (8-K) Sep 8, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share | GPCR | Nasdaq |
| Ordinary shares, par value $0.0001 per share | Nasdaq |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Structure Therapeutics Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 74 risks under these headings, as written.4
- Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
- We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
- We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development programs, commercialization efforts or other operations.
- Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- Risks Related to the Discovery, Development and Regulatory Approval of Product Candidates
- Our approach to the discovery of product candidates based on our technology platform is unproven, and we do not know whether we will be able to develop any products of commercial value.
- We are early in our development efforts and only have five product candidates — aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578 and ACCG-3535 — in early clinical development. All of our other development programs are in the preclinical or discovery stage. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
- Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes. The results of prior clinical studies and preclinical studies are not necessarily predictive of future results, and may not be favorable, or receive regulatory approval on a timely basis, if at all.
- Any difficulties or delays in the commencement or completion, or termination or suspension, of our ongoing and planned clinical studies could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
- Enrollment and retention of patients in clinical studies is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects.
- Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate.
- As an organization, we have never conducted later-stage clinical studies or submitted an NDA, and may be unable to do so for any of our product candidates.
The other 63 risks
- The marketing approval processes of the FDA and applicable foreign authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.
- We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- We may not be able to obtain or maintain orphan drug designations or exclusivity for our product candidates, which could limit the potential profitability of our product candidates.
- We have conducted, or plan to conduct, our initial clinical studies for aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578, ACCG-3535 and our other product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such studies, in which case our development plans will be delayed, which could materially harm our business.
- Preliminary, topline and interim data from our clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Obtaining and maintaining marketing approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions.
- International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
- Disruptions to the operations of the FDA, the SEC, other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, staffing cuts or other staffing shortages, along with uncertainty regarding the potential for new initiatives, laws, regulations, policies and guidance affecting our product candidates or other aspects of our business, could materially and adversely affect our business.
- Risks Related to Our Reliance on Third Parties
- We rely on third parties for the manufacture of our product candidates for preclinical and clinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
- Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.
- We rely on third parties to conduct, supervise and monitor our discovery research, preclinical studies and clinical studies. We have experienced delays due to actions of third parties in the past and if in the future third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
- We have entered into, and may in the future enter into, collaboration agreements and strategic alliances to maximize the potential of our structure-based drug discovery platform and product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.
- Our existing discovery collaborations with Schrödinger, LLC (together with its affiliates, “Schrödinger”) are important to our business. If we are unable to maintain these collaborations, or if these collaborations are not successful, our business could be adversely affected.
- Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
- The adoption and deployment of AI in our, and any third-party collaborators’ operations, and in particular our and any third-party collaborators’ R&D efforts to explore new targets and develop effective products, may not be effective and may expose us to risk.
- Risks Related to Commercialization of Our Product Candidates
- Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.
- Even if our current or future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
- Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.
- We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.
- If the market opportunities for any of our product candidates are smaller than we estimate, even assuming approval of a product candidate, our revenue may be adversely affected, and our business may suffer.
- We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
- Our future growth may depend, in part, on our ability to commercialize products in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
- Risks Related to Our Business Operations and Industry
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
- We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed.
- We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
- Our relationships with customers, physicians and other healthcare providers, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Healthcare legislative reform measures may have a negative impact on our business and results of operations.
- If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.
- If our information technology systems or data, or those of third parties upon which we rely, are or were compromised or experienced significant disruptions of our information technology systems or data security incidents, we could experience adverse consequences including but not limited to significant financial, legal, regulatory, business and reputational harm; litigation; fines and penalties; disruptions of our business operations; loss of revenue or profits; loss of customers or sales; or other adverse consequences.
- We conduct certain research and development operations through our Australian wholly-owned subsidiaries. We have voluntarily refunded a research and development tax credit previously received under Australian regulations. If we lose our ability to operate in Australia, or if any of our subsidiaries are unable to receive the research and development tax credit allowed by Australian regulations, or are required to refund any research and development tax credit previously received or reserve for such credit in our financial statements, our business and results of operations could suffer.
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
- There is tax risk associated with the reporting of cross-border arrangements and activities between us and our subsidiaries.
- Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.
- Risks Related to Doing Business in China and Our International Operations
- Changes in the political and economic policies or in relations between China and the United States may affect our business, financial condition, results of operations and the market price of our ADSs.
- Changes in U.S. and Chinese regulations may impact our business, our operating results, our ability to raise capital and the market price of our ADSs.
- Compliance with China’s current Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business.
- The approval of, filing or other procedures with the CSRC or other Chinese regulatory authorities may be required in connection with issuing securities to foreign investors under Chinese law, and, if required, we cannot predict whether we will be able, or how long it will take us, to obtain such approval or complete such filing or other procedures.
- Pharmaceutical companies operating in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our current and planned operations in China.
- As a company with operations and business relationships outside of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations.
- If we fail to comply with Chinese environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- Development in the Chinese legal system could materially and adversely affect us.
- We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (the “FCPA”), U.S. domestic bribery laws, and similar anti-corruption and anti-bribery laws of China and other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.
- Regulatory Requirements on currency exchange may limit our ability to receive and use effectively financing in foreign currencies.
- Chinese regulations relating to the establishment of offshore special purpose companies by residents in China may subject our China resident beneficial owners or our wholly foreign-owned subsidiaries in China to liability or penalties, limit our ability to inject capital into these subsidiaries, limit these subsidiaries’ ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us.
- If we are classified as a China resident enterprise for China income tax purposes, such classification could result in unfavorable tax consequences to us and our non-Chinese shareholders or ADS holders.
- We and our shareholders face uncertainties in China with respect to indirect transfers of equity interests in China resident enterprises.
- Any failure to comply with Chinese regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.
- Risks Related to Our Intellectual Property
- If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
- We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.
- We rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may rely on one or more in-licenses from third parties. If we lose these rights, our business may be materially adversely affected, and if disputes arise with one or more licensors, we may be subjected to future litigation as well as the potential loss of or limitations on our ability to develop and commercialize products and technologies covered by these license agreements.
- Our intellectual property licensed from third parties may be subject to retained rights.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- Intellectual property rights do not necessarily address all potential threats to our business.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
- Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.
Legal proceedings
To the best of our knowledge, we are not currently the subject of any material governmental investigation, private lawsuit or other legal proceeding. From time to time, we are and may in the future be involved in legal and regulatory proceedings or investigations concerning matters that arise in the ordinary course of our business and that could result in significant fines or penalties, have an adverse impact on our reputation, business and financial condition or results of operations and divert the attention of our management from the operation of our business.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARJun Yoon, Chief financial officer
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARXichen Lin, Chief Scientific Officer
- 19SEC EDGARYingli Ma, Chief Technology Officer
- 20SEC EDGARDaniel G. Welch, Board member
- 21SEC EDGAREric Dobmeier, Board member
- 22SEC EDGARJoanne Waldstreicher, Board member
- 23SEC EDGARRamy Farid, Board member
- 24SEC EDGARSharon Tetlow, Board member
- 25SEC EDGARTed W. Love, Board member
- 26
- 27
- 28SEC EDGARResults of operations
- 29SEC EDGARShareholder vote
- 30
- 31
- 32
- 33SEC EDGARResults of operations
- 34SEC EDGAREntered a material agreement
- 35SEC EDGAROther events
- 36
- 37SEC EDGARResults of operations
- 38SEC EDGARResults of operations
- 39NasdaqNasdaq calendar
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55